Rep. Gilbert Ray Cisneros, Jr. Buys Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Stock
by Kim Johansen · The Markets DailyRepresentative Gilbert Ray Cisneros, Jr. (Democratic-California) recently bought shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO). In a filing disclosed on April 07th, the Representative disclosed that they had bought between $1,001 and $15,000 in Agios Pharmaceuticals stock on March 3rd. The trade occurred in the Representative’s “150 MAIN STREET TRUST > BANK OF AMERICA” account.
Representative Gilbert Ray Cisneros, Jr. also recently made the following trade(s):
- Sold $1,001 – $15,000 in shares of MACOM Technology Solutions (NASDAQ:MTSI) on 3/27/2026.
- Purchased $1,001 – $15,000 in shares of StandardAero (NYSE:SARO) on 3/27/2026.
- Purchased $1,001 – $15,000 in shares of FirstService (NASDAQ:FSV) on 3/27/2026.
- Sold $1,001 – $15,000 in shares of Charles Schwab (NYSE:SCHW) on 3/27/2026.
- Sold $1,001 – $15,000 in shares of Advanced Energy Industries (NASDAQ:AEIS) on 3/27/2026.
- Sold $1,001 – $15,000 in shares of Flex (NASDAQ:FLEX) on 3/27/2026.
- Purchased $1,001 – $15,000 in shares of LPL Financial (NASDAQ:LPLA) on 3/27/2026.
- Purchased $1,001 – $15,000 in shares of DoorDash (NASDAQ:DASH) on 3/27/2026.
- Sold $1,001 – $15,000 in shares of Viavi Solutions (NASDAQ:VIAV) on 3/27/2026.
- Purchased $15,001 – $50,000 in shares of Fabrinet (NYSE:FN) on 3/27/2026.
Agios Pharmaceuticals Price Performance
AGIO remained flat at $32.92 during trading on Friday. The company’s stock had a trading volume of 765,236 shares, compared to its average volume of 942,765. Agios Pharmaceuticals, Inc. has a one year low of $22.24 and a one year high of $46.00. The business’s fifty day moving average price is $29.34 and its two-hundred day moving average price is $32.11. The company has a market cap of $1.93 billion, a price-to-earnings ratio of -4.63 and a beta of 0.79.
Insider Buying and Selling
In other Agios Pharmaceuticals news, insider Krishnan Viswanadhan sold 2,959 shares of the company’s stock in a transaction on Thursday, March 5th. The stock was sold at an average price of $27.80, for a total value of $82,260.20. Following the completion of the sale, the insider directly owned 5,141 shares in the company, valued at $142,919.80. This represents a 36.53% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Cecilia Jones sold 3,141 shares of the company’s stock in a transaction on Thursday, April 2nd. The shares were sold at an average price of $34.71, for a total value of $109,024.11. Following the completion of the sale, the chief financial officer owned 54,998 shares of the company’s stock, valued at approximately $1,908,980.58. The trade was a 5.40% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold 15,582 shares of company stock worth $520,405 over the last quarter. Corporate insiders own 4.30% of the company’s stock.
Wall Street Analyst Weigh In
AGIO has been the topic of a number of research analyst reports. Weiss Ratings reaffirmed a “sell (d)” rating on shares of Agios Pharmaceuticals in a research note on Friday, March 27th. Truist Financial lifted their price target on Agios Pharmaceuticals from $32.00 to $38.00 and gave the stock a “buy” rating in a research note on Wednesday, December 24th. HC Wainwright lifted their price target on Agios Pharmaceuticals from $62.00 to $65.00 and gave the stock a “buy” rating in a research note on Thursday, February 12th. Leerink Partners lifted their price target on Agios Pharmaceuticals from $34.00 to $40.00 and gave the stock an “outperform” rating in a research note on Friday, December 26th. Finally, The Goldman Sachs Group upped their target price on shares of Agios Pharmaceuticals from $28.00 to $32.00 and gave the stock a “neutral” rating in a report on Wednesday, April 1st. Six equities research analysts have rated the stock with a Buy rating, four have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Hold” and a consensus target price of $42.67.
View Our Latest Stock Analysis on AGIO
Institutional Investors Weigh In On Agios Pharmaceuticals
Hedge funds have recently modified their holdings of the business. T. Rowe Price Investment Management Inc. acquired a new stake in shares of Agios Pharmaceuticals in the fourth quarter valued at about $25,000. Assetmark Inc. grew its holdings in Agios Pharmaceuticals by 37.9% in the 4th quarter. Assetmark Inc. now owns 1,317 shares of the biopharmaceutical company’s stock valued at $36,000 after buying an additional 362 shares in the last quarter. NewEdge Advisors LLC purchased a new stake in Agios Pharmaceuticals in the 1st quarter valued at $40,000. First Horizon Corp purchased a new stake in Agios Pharmaceuticals in the 3rd quarter valued at $45,000. Finally, Caitong International Asset Management Co. Ltd purchased a new stake in Agios Pharmaceuticals in the 4th quarter valued at $49,000.
About Representative Cisneros
Gil Cisneros (Democratic Party) is a member of the U.S. House, representing California’s 31st Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027.
Cisneros (Democratic Party) is running for re-election to the U.S. House to represent California’s 31st Congressional District. He declared candidacy for the 2026 election.
Gil Cisneros served in the U.S. Navy as a supply officer from 1994 to 2004. Cisneros earned a bachelor’s degree in political science from George Washington University in 1994, a master’s in business administration from Regis University in 2002, and a master’s degree in urban education policy from Brown University in 2015. His career experience includes working as a logistics manager for Frito-Lay. In 2010, Cisneros won the lottery and became involved in activism and philanthropy, founding a scholarship program for local high school students. In 2021, President Joe Biden (D) appointed Cisneros as under secretary of defense for personnel and readiness.
Agios Pharmaceuticals Company Profile
Agios Pharmaceuticals, Inc is a biopharmaceutical company founded in 2008 as a spin-out from research at Dana-Farber Cancer Institute and the Broad Institute. Headquartered in Cambridge, Massachusetts, Agios focuses on understanding and targeting cellular metabolism to develop novel therapies for cancer and rare genetic diseases. The company’s scientific platform integrates genomic discovery, metabolic profiling and precision medicine approaches to identify and advance small-molecule candidates that correct or exploit metabolic dysfunction.
Agios’s lead products are IDH (isocitrate dehydrogenase) inhibitors that target specific cancer mutations.